Bonus Biogroup: The Investigation Overhang And The Option-Loan Structure As A Hidden Cost Of Capital

The main article already established that Bonus Biogroup’s central bottleneck is funding the next stage. This follow-up isolates a different layer, one that does not sit only in the cash line but in the credibility the capital market is expected to give the company: the legal overhang, the legacy option-loan structure, and the way the chairman and CEO service agreements turn both share appreciation and financing events into compensation events.

There are four points that matter most here:

• The investigation is no longer at the noise stage. In early January 2026 the file was transferred to the Tax and Economics Prosecutor’s Office, and by the time the accounts were approved there was still no final decision on whether proceedings would be taken.
• The same legacy loan structure is still alive inside the report. The option-loan balance stood at NIS 3.106 million at year end 2025, and even by the approval date NIS 1.559 million was still outstanding.
• Part of 2025 liquidity depended on management not drawing accrued pay. Related-party payables rose to NIS 7.88 million, almost entirely because chairman and CEO fees were left unpaid.
• The compensation agreements themselves link capital to pay. The disclosed bonus mechanisms are tied not only to share performance, but also to an additional listing and to equity raises above certain thresholds.

The Overhang Has Moved From Search To Prosecution Review

The easiest mistake is to read this issue as an old controversy that has faded. It is true that the two motions to certify class actions filed in February 2022 against the company and its controlling shareholder were withdrawn in June 2024, and the court approved that withdrawal without compensation. But that is only the end of one track.

The second track, the regulatory and potentially criminal one, actually moved forward. In February 2024 investigators from the Israel Securities Authority arrived at the company’s offices to conduct a search. According to the company’s own description, several officers were called in for questioning, including Dr. Shai Martzky, the controlling shareholder, CEO, and director, and Yosef Roich, the chairman. The disclosed suspicions are broad: securities fraud, insider trading, aggravated fraud, money laundering, reporting offenses, and misleading details connected to loans given to employees for exercising options.

The critical date is the later one, not the earlier one. In early January 2026 the company says it was informed that the Authority had completed its investigation and transferred the file to the Tax and Economics Prosecutor’s Office to examine whether indictments should be filed, including against Martzky and Roich. As of the approval date, no decision had yet been made, and the company writes explicitly that it cannot assess the outcome of that review or its possible consequences for the business and financial position. It also says that if proceedings are taken, they could adversely affect the company’s business and operating results.

That is the core point. The withdrawal of the civil motions did not clear the governance cloud. It merely left investors facing a heavier track, where the key decision no longer sits with private plaintiffs but with prosecutors.

The Option Loans Are Not A Historical Footnote

The reason the investigation matters directly for cost of capital is not only its existence. It also relates to the specific subject that still appears inside the annual report itself: loans given to employees in order to exercise options.

During 2022, 8.425 million company options were exercised for aggregate consideration of about NIS 4.651 million. At the same time, the company extended loans of NIS 3.271 million to employees and NIS 1.38 million to an officer. In practice, the loan amount matched the full exercise consideration. Put differently, the company financed the entire exercise price itself.

Those loans were non-interest-bearing and described in substance as non-recourse loans. That matters because the economics of such a structure are very different from a standard equity commitment by employees or officers. The holder gets the shares, but part of the downside on the exercise price is not really sitting with that holder in full. From the outside, this looks less like clean equity coming in and more like a company-built structure that enabled option exercise without the full cash burden truly landing on the exercising parties.

The issue did not stay in 2022. At the end of 2025, the remaining loan balance still stood at NIS 3.106 million, and on December 28, 2025 the board approved an extension of the repayment date through June 30, 2026. By the date the accounts were approved, the balance had declined to NIS 1.559 million after share sales by an officer and two former employees led to NIS 1.557 million of sale proceeds being remitted to the company, while the remaining unpaid balance was cancelled. The company emphasizes that this cancellation did not reduce its assets and did not affect comprehensive loss or cash flows.

From an accounting perspective, that may look relatively clean. From a governance perspective, it reads very differently. Once the investigation note itself says that the suspected misleading reporting relates to these option loans, it becomes hard to dismiss the structure as a minor technical remainder from the past. It turns into active memory that the market carries into the next financing round.

This chart makes the point visually. Even three years after the option exercises, and at exactly the point when the investigation file has moved to prosecutors, the structure has still not fully disappeared.

The Compensation Agreements Link Fundraising To Pay

The second layer of hidden capital cost sits in the related-party note. The company is controlled by Dr. Shai Martzky, who also serves as CEO and director and held 32.97% of the shares as of December 31, 2025. Chairman Yosef Roich held another 11.48%. These are not simply two senior executives. They are also two material control points in the ownership structure, and both appear again in the legal note.

Both of them operate under shareholder-approved service agreements. Under the disclosed terms, Roich is entitled to fixed monthly compensation of NIS 80 thousand and Martzky to NIS 106 thousand. When no employer-employee relationship exists, the cost is multiplied by a factor of 1.4. Beyond that, both are entitled to a bonus derived from the change in the company’s share price relative to the TA Biomed index, up to a ceiling of 12 months of fixed compensation cost per year, with up to three months payable in cash and the balance in company shares.

But that is not where the mechanism stops. The same note also provides for an additional bonus if the company’s shares are listed on another exchange, and in connection with share issuances to an investor group against actual cash receipts of at least $6 million or $10 million within 18 months. In that case, Martzky and Roich are entitled to a cash bonus equal to 4 or 6 months of fixed compensation cost. Based on the disclosed monthly rates, that means roughly NIS 1.04 million or NIS 1.56 million of cash for the two of them together.

That is precisely the point at which a compensation structure becomes a hidden capital cost. If an additional listing or a large equity raise is supposed to help solve the funding problem, the same event may also activate additional pay for the two people who both run and help control the company.

The report already shows that this is not theoretical. In 2025, due to the increase in the share price, Martzky and Roich became entitled to bonuses of NIS 697 thousand and NIS 538 thousand in cash, plus NIS 262 thousand and NIS 230 thousand in shares, respectively. In addition, the expenses recognized in the accounts in 2025 for their compensation amounted to about NIS 2.045 million for Martzky and NIS 1.548 million for Roich.

The figure that really changes the funding read sits in the payables line. Related-party payables jumped to NIS 7.88 million at the end of 2025, versus NIS 3.038 million a year earlier. Of that balance, NIS 4.434 million related to the chairman’s unpaid fees and NIS 3.355 million to the CEO’s unpaid fees. In other words, almost the entire balance consists of cash that had not actually left the company to the two most powerful individuals in its control and management structure.

This is a two-sided figure. On one hand, it keeps cash inside the company and therefore eases short-term liquidity pressure. On the other hand, it means that part of the 2025 bridge was built not only from outside capital, but also from compensation that stayed in the company. So when investors look at liquidity, they cannot really separate the capital-markets story from the financial relationship between the company and the two people with the most power inside it.

Why This Is A Hidden Cost Of Capital

Cost of capital does not have to appear only as interest expense or a going-concern note. In a life-sciences company that still needs to persuade investors to fund the road to late-stage trials and commercialization, cost of capital can also show up through a lower raise price, extra warrants, a narrower investor base, or simply a need for more proof before money comes in.

That is exactly what begins to emerge here. Outside investors are not receiving only a scientific and regulatory story. They are receiving a bundle: an investigation file that has reached prosecutors, a legacy option-loan structure that sits inside the very suspicion of misleading disclosure, and two central officers whose compensation is linked not only to share performance but also to capital-market events. On top of that sits a NIS 7.88 million related-party payable balance that is almost entirely connected to those same two individuals.

The implication is not that raising capital has become impossible. It does mean that future fundraisings will also have to deal with a credibility discount. In a company like this, the market is not pricing only the scientific or regulatory risk of the assets. It is also pricing the cleanliness of the governance structure, the quality of the capital coming in, and whether each financing event primarily serves the company or also activates another layer of internal compensation.

The most interesting point is that the two mechanisms, the option loans and the related-party accruals, pull in opposite short-term directions. The first once helped create apparent equity through option exercises. The second helped keep cash inside the company during 2025. But they share one cost: both make it harder for outside investors to see a simple, clean, final capital structure.

Bottom Line

The main article described a company that still needs capital to reach the next stage. This follow-up adds that the capital is likely to remain more expensive than it first appears, not only because of clinical or regulatory risk, but because of the governance package that sits around it.

This is the real story. The same annual report holds together the transfer of the investigation file to prosecutors, the long tail of the option-loan structure, and the compensation agreements that turn share appreciation, an additional listing, and equity financing into events with an internal price tag. For a company that will continue to depend on capital markets, this is no longer a footnote. It is a hidden cost of capital.

A cleaner read would have to come from three places: closure or narrowing of the legal cloud, full elimination of the remaining option-loan balance, and evidence that the company can raise capital without again relying on a build-up in related-party payables and without loading each financing event with another compensation trigger.